Regulus Therapeutics gains despite a mixed Q2 report; revenue rises

Regulus Therapeutics (RGLS +8.6%) moves up despite posting a mixed Q2, improving on last year but still coming up short versus consensus on a per share basis.

Net loss per share was negatively impacted by its initial public offering and concurrent common stock issuances in October 2012.

R&D expenses also rose, largely due to the expansion of R&D personnel and an increase in IND-enabling activities for RG-101 in the first half of 2013.

Revenues rose to $4.76M from $3.3M, topping estimates looking for $3.41M.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs